May 24, 2019 Acad, Gov/Utilities Clinical Research/Diagn. Product Launch

QIAGEN launches first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer

Germantown, Maryland, and Hilden, Germany, May 24, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the immediate launch of its therascreen® PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in identifying breast cancer patients eligible for treatment with PIQRAY (alpelisib), a... Read more

May 23, 2019 Atomic Spectroscopy

QIAGEN and U.K. alliance launch APIS Assay Technologies to expand biomarker research and foster healthcare innovation

Manchester, United Kingdom, and Hilden, Germany, May 23, 2019 – QIAGEN and leading U.K.-based organizations today launched APIS Assay Technologies Ltd., a company that aims to improve the success rate of biomarker commercialization by bridging the translational gap that often exists between the discovery of genomic markers and industry’s development of new diagnostics. APIS will... Read more

May 21, 2019 Clinical Research/Diagn. PR/Corporate

QIAGEN’s QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation

Hilden, Germany and Germantown, Maryland, May 21, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution under development for diagnosis of latent tuberculosis (TB) infection in low-resource regions with a high disease burden of tuberculosis, will be recognized by the Joint United Nations Programme on HIV/AIDS... Read more

May 20, 2019 Acad, Gov/Utilities Liq. Handling & Robotics Microscopy Product Launch

QIAGEN gains 510(k) clearance by FDA for QIAstat-Dx in the U.S. and launches system as next generation platform for syndromic insights

Germantown, Maryland, and Hilden, Germany, May 20, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its QIAstat-Dx syndromic testing system after receiving 510(k) clearance by the U.S. Food and Drug Administration, along with the multiplex QIAstat-Dx® Respiratory Panel for simultaneous qualitative detection and identification of multiple respiratory... Read more

May 16, 2019 Clinical Research/Diagn.

QIAGEN and Inovio collaborate to develop companion diagnostic for novel immunotherapy targeting precancerous cervical lesions

Hilden, Germany, Germantown, Maryland, and Plymouth Meeting, Pennsylvania, May 16, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Inovio Pharmaceuticals Inc. (NASDAQ: INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV).... Read more

May 6, 2019 PR/Corporate

Ad hoc Announcement according to Art. 17 Market Abuse Regulation

QIAGEN to conduct an additional up to $100 million share repurchase program Venlo, The Netherlands, May 6, 2019 – QIAGEN N.V. announces that its Managing Board, upon authorization of the Supervisory Board, has today passed a resolution to exercise the authorization granted by the General Meeting of Shareholders on June 19, 2018, and to purchase shares in the... Read more

April 12, 2019 Acad, Gov/Utilities Clinical Research/Diagn. Product Launch

QIAGEN launches first FDA-approved companion diagnostic using FGFR alterations to help guide the treatment of metastatic urothelial cancer

Germantown, Maryland, and Hilden, Germany, April 12 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its novel therascreen® FGFR RGQ RT-PCR Kit (therascreen FGFR Kit) as a companion diagnostic to help guide the use of the newly approved FGFR kinase inhibitor, BALVERSA™ (erdafitinib), developed by Janssen Biotech,... Read more

April 11, 2019 Clinical Research/Diagn.

QIAGEN’s QuantiFERON®-TB passes milestone of 60 million tests in global fight against tuberculosis, current annual run rate exceeds 12 million tests

Hilden, Germany; Germantown, Maryland; and Amsterdam, Netherlands, April 11, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its modern gold standard QuantiFERON®-TB test for detection of latent tuberculosis (TB) infections has surpassed 60 million tests administered, having impacted the lives of millions of patients worldwide and supporting the global fight... Read more

April 11, 2019 Clinical Research/Diagn. Life Science Tools M&A, Partnerships Product Launch

QIAGEN and NeuMoDx expand assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe and also announce availability of NeuMoDx 96 version

Hilden, Germany, and Ann Arbor, Michigan, April 11, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced an expansion of the content menu for the NeuMoDx™ 96 and 288 Molecular Systems, as well as the commercial availability of the NeuMoDx 96 mid-throughput version of this family of fully... Read more